Combination antibiotic therapy is often indicated for health care-associated pneumonia due to resistant pathogens and is recommended in the Infectious Diseases Society of America/American Thoracic Society guidelines on the management of community-acquired pneumonia and health care-associated pneumonia (1, 4). Antibiotic aerosolization enhances delivery to the lower respiratory tract while theoretically limiting toxicity. Aerosolized tobramycin (TOBI) is currently approved for use only in patients with cystic fibrosis (CF). According to the manufacturer (2007 tobramycin inhalation solution USP prescribing information, Novartis Pharmaceuticals, East Hanover, NJ), patients with normal renal function do not require routine tobramycin concentrat...
In patients with bronchiectasis (BE), infection with Pseudomonas aeruginosa (Pa) results in disease ...
Objectives: Better treatment outcomes in cystic fibrosis (CF) may be expected by changing standard t...
AIMS: We aimed to compare the pharmacokinetics (PK) and safety profile of tobramycin inhalation solu...
Combination antibiotic therapy is often indicated for health care-associated pneumonia due to resist...
This study was performed to determine the clinical pharmacokinetics of tobramycin in six patients wi...
AbstractBackgroundNebulization times have been identified as an issue in patient compliance with tob...
Chronic airway infection with Pseudomonas aeruginosa is a major cause of increased morbidity and mor...
BACKGROUND: Use of inhaled tobramycin therapy for treatment of Pseudomonas aeruginosa infections in ...
This randomized, multicentre, open-label, two-period crossover study showed that inhaling tobramycin...
Background: The clinical effectiveness of inhaled tobramycin depends on the dose reaching the desire...
Data on the pharmacokinetics of antibiotics after inhalation are limited. The aim of this pilot stud...
AbstractBackgroundUse of inhaled tobramycin therapy for treatment of Pseudomonas aeruginosa infectio...
AbstractEarly studies of the use of antibiotics in patients with cystic fibrosis suggested that they...
Tobramycin dry powder formulations were evaluated by gamma scintigraphy and pharmacokinetic methods....
AIMS: We aimed to compare the pharmacokinetics (PK) and safety profile of tobramycin inhalation solu...
In patients with bronchiectasis (BE), infection with Pseudomonas aeruginosa (Pa) results in disease ...
Objectives: Better treatment outcomes in cystic fibrosis (CF) may be expected by changing standard t...
AIMS: We aimed to compare the pharmacokinetics (PK) and safety profile of tobramycin inhalation solu...
Combination antibiotic therapy is often indicated for health care-associated pneumonia due to resist...
This study was performed to determine the clinical pharmacokinetics of tobramycin in six patients wi...
AbstractBackgroundNebulization times have been identified as an issue in patient compliance with tob...
Chronic airway infection with Pseudomonas aeruginosa is a major cause of increased morbidity and mor...
BACKGROUND: Use of inhaled tobramycin therapy for treatment of Pseudomonas aeruginosa infections in ...
This randomized, multicentre, open-label, two-period crossover study showed that inhaling tobramycin...
Background: The clinical effectiveness of inhaled tobramycin depends on the dose reaching the desire...
Data on the pharmacokinetics of antibiotics after inhalation are limited. The aim of this pilot stud...
AbstractBackgroundUse of inhaled tobramycin therapy for treatment of Pseudomonas aeruginosa infectio...
AbstractEarly studies of the use of antibiotics in patients with cystic fibrosis suggested that they...
Tobramycin dry powder formulations were evaluated by gamma scintigraphy and pharmacokinetic methods....
AIMS: We aimed to compare the pharmacokinetics (PK) and safety profile of tobramycin inhalation solu...
In patients with bronchiectasis (BE), infection with Pseudomonas aeruginosa (Pa) results in disease ...
Objectives: Better treatment outcomes in cystic fibrosis (CF) may be expected by changing standard t...
AIMS: We aimed to compare the pharmacokinetics (PK) and safety profile of tobramycin inhalation solu...